Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer and sought associations between the mutation status of the KRAS gene in tumors and clinical response to cetuximab. METHODS: We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab. The primary end point was progression-free survival. RESULTS: A total of 599 patients received cetuximab plus FOLFIRI, and 599 received FOLFIRI alone. The hazard ratio for progression-free survival in the cetuximab-FOLFIRI group as compared with the FOLFIRI group was 0.85 (95% confidence interval [CI], 0.72 to 0.99; P=0.048). There was no significant difference in the overall survival between the two treatment groups (hazard ratio, 0.93; 95% CI, 0.81 to 1.07; P=0.31). There was a significant interaction between treatment group and KRAS mutation status for tumor response (P=0.03) but not for progression-free survival (P=0.07) or overall survival (P=0.44). The hazard ratio for progression-free survival among patients with wild-type-KRAS tumors was 0.68 (95% CI, 0.50 to 0.94), in favor of the cetuximab-FOLFIRI group. The following grade 3 or 4 adverse events were more frequent with cetuximab plus FOLFIRI than with FOLFIRI alone: skin reactions (which were grade 3 only) (in 19.7% vs. 0.2% of patients, P<0.001), infusion-related reactions (in 2.5% vs. 0%, P<0.001), and diarrhea (in 15.7% vs. 10.5%, P=0.008). CONCLUSIONS: First-line treatment with cetuximab plus FOLFIRI, as compared with FOLFIRI alone, reduced the risk of progression of metastatic colorectal cancer. The benefit of cetuximab was limited to patients with KRAS wild-type tumors. (ClinicalTrials.gov number, NCT00154102.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Sub-analysis revealed that the benefits of cetuximab were limited to patients with KRAS wild-type (wt) tumors.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [16]
In the citing paper
“The results of this trial demonstrated a decrease in progression-free survival but no difference in overall survival.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [16]
In the citing paper
“Some large clinical trials have shown that FOLFIRI (leucovorin + 5-FU + irinotecan) or FOLFOX regimens combined with EGFR inhibitors can benefit KRAS-WT CRC.”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [150]
In the citing paper
“However, CRC with KRAS mutations do not benefit from EGFR inhibitors, possibly because activation of KRAS does not depend upstream on EGFR [149,150,151,152].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [150]
In the citing paper
“According to the CRYSTAL trial, the application of cetuximab and FOLFIRI in first-line treatment can reduce the risk of progression by 15% and increase overall survival (OS) by 8.2 months in patients who have KRAS WT mCRC compared with patients taking FOLFIRI alone [5].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [5]
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Statistical Methods for Rates and Proportions, 2nd ed
GROVE, W. A. (1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.12.1644-a · Cited by 3,748
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Self-citationWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Research works printed but not linked: 3
- Rougier P, 2004, J Clin Oncol, 22, 248s, 10.1200/jco.2004.22.14_suppl.3513 · doi:10.1200/jco.2004.22.14_suppl.3513
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Schilsky RL, 2002, Clin Cancer Res, 8, 935
Cited by
Items 401–500 of 1,017
Gagnière, J., Dupré, A., Gholami, S., Pezet, D., Boerner, T., Gönen, M., Kingham, T. P., Allen, P. J., Balachandran, V. P., DeMatteo, R. P., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002968 · Cited by 107
EPMA position paper in cancer: current overview and future perspectives
Grech, G., Zhan, X., Yoo, B. C., Bubnov, R. V., Hagan, S., Danesi, R., Vittadini, G., & Desiderio, D. M. (2015) · The EPMA Journal · doi:10.1186/s13167-015-0030-6 · Cited by 109
Shi, Q., de Gramont, A., Grothey, A., Zalcberg, J. R., Chibaudel, B., Schmoll, H., Seymour, M., Adams, R., Saltz, L. B., Goldberg, R. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.5887 · Cited by 110
“Table 4 compares the predicted HRs for OS by using the regression models based on all studies and studies testing targeted regimens only, with the actual observed HRs for OS for the two validation studies.(37,39) Because the observed correlation between treatment effects on PFS and OS was only moderate, the prediction…”
MethodThe Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer
Chen, Y., Zheng, X., & Wu, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.792691 · Cited by 116
Liver transplantation for colorectal liver metastases: revisiting the concept
Foss, A. E., Adam, R. A., & Dueland, S. (2010) · Transplant International · doi:10.1111/j.1432-2277.2010.01097.x · Cited by 100
“Cetuximab and panitumumab (EGFR antibody) provides increased response rates in patients with K-ras wild type tumors [12,13].”
BackgroundThe management of resectable and unresectable liver metastases from colorectal cancer
Kemeny, N. E. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32833a6c8a · Cited by 106
Ychou, M., Rivoire, M. L., Thézenas, S., Quénet, F., Delpéro, J., Rebischung, C., Létoublon, C., Guimbaud, R., François, É., Ducreux, M. P., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3217-x · Cited by 100
New Paradigms in Post-hepatectomy Liver Failure
Golse, N., Bucur, P. O., Adam, R., Castaing, D., Sa Cunha, A., & Vibert, E. (2013) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-012-2048-6 · Cited by 100
Kyula, J. N., Van Schaeybroeck, S., Doherty, J., Fenning, C. S., Longley, D. B., & Johnston, P. G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0014 · Cited by 99
“Clin Cancer Res; 16(13) July 1, 2010 enhance response rates in patients with advanced CRC and thereby improve survival rates compared with those obtained with combined EGFR monoclonal antibody inhibition (cetuximab)/chemotherapy treatment (33).”
BackgroundShubert, C. R., Habermann, E. B., Bergquist, J. R., Thiels, C. A., Thomsen, K. M., Kremers, W. K., Kendrick, M. L., Cima, R. R., & Nagorney, D. M. (2015) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-015-2895-z · Cited by 99
Khattak, M. A., Martin, H. L., Davidson, A., & Phillips, M. R. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.12.011 · Cited by 116
Oki, E., Emi, Y., Kojima, H., Higashijima, J., Kato, T., Miyake, Y., Kon, M., Ogata, Y., Takahashi, K. P., Ishida, H., et al. (2015) · International Journal of Clinical Oncology · doi:10.1007/s10147-015-0784-9 · Cited by 99
Treatment Decisions After Diagnosis of Metastatic Colorectal Cancer
Cartwright, T. H. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.11.001 · Cited by 111
The development of immunoconjugates for targeted cancer therapy
Smaglo, B. G., Aldeghaither, D. S., & Weiner, L. M. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.159 · Cited by 109
Treatment of colorectal liver metastases
Ismaili, N. (2011) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-9-154 · Cited by 108
Golkhalkhali, B., Rajandram, R., Paliany, A. S., Ho, G. F., Wan Ishak, W. Z., Johari, C. S., & Chin, K. F. (2018) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12758 · Cited by 96
“Self-employed 1 (1) 2 (3) Retired 51 (73) 42 (60)”
Influentialc-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival
Lee, S. J., Lee, J., Park, S. H., Park, J. O., Lim, H. Y., Kang, W. K., Park, Y. S., & Kim, S. T. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.02.013 · Cited by 100
Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib
Otsuka, T., Eguchi, Y., Kawazoe, S., Yanagita, K., Ario, K., Kitahara, K., Kawasoe, H., Kato, H., Mizuta, T., & the Saga Liver Cancer Study Group (2012) · Hepatology Research · doi:10.1111/j.1872-034x.2012.00991.x · Cited by 100
Pulmonary toxicities from targeted therapies: a review
Barber, N. A., & Ganti, A. K. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0199-0 · Cited by 101
Lee, M. S., McGuffey, E. J., Morris, J. S., Manyam, G., Baladandayuthapani, V., Wei, W., Morris, V. K., Overman, M. J., Maru, D. M., Jiang, Z.-Q., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.87 · Cited by 98
“Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I, Kohne CH (2012) Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.”
BackgroundInfluentialChallenges in Antibody Development against Tn and Sialyl-Tn Antigens
Loureiro, L. R., Carrascal, M. A., Barbas, A., Ramalho, J. S., Novo, C., Delannoy, P., & Videira, P. A. (2015) · Biomolecules · doi:10.3390/biom5031783 · Cited by 115
Custodio, A., & Feliú, J. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.05.001 · Cited by 110
“[8] Van Cutsem E, Kohne CH, Hitre E, et al.”
BackgroundFOLFOX/FOLFIRI pharmacogenetics: The call for a personalized approach in colorectal cancer therapy
Mohelníková-Duchoňová, B., Melichar, B., & Soucek, P. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i30.10316 · Cited by 116
Hadden, W. J., de Reuver, P. R., Brown, K. M., Mittal, A., Samra, J. S., & Hugh, T. J. (2016) · HPB · doi:10.1016/j.hpb.2015.12.004 · Cited by 110
Role of targeted therapy in metastatic colorectal cancer
Ohhara, Y., Fukuda, N., Takeuchi, S., Honma, R., Shimizu, Y., Kinoshita, I., & Dosaka-Akita, H. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i9.642 · Cited by 96
Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis
Brandi, G. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i2.519 · Cited by 96
Hiraki, M., Nishimura, J., Takahashi, H., Wu, X., Takahashi, Y., Miyo, M., Nishida, N., Uemura, M., Hata, T., Takemasa, I., et al. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.5 · Cited by 95
Pellino, G., Gallo, G., Pallante, P., Capasso, R., Stefano, A. D., Maretto, I., Malapelle, U., Qiu, S., Nikolaou, S., Barina, A., et al. (2018) · Gastroenterology Research and Practice · doi:10.1155/2018/2397863 · Cited by 105
“The Cetuximab Combined With Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer (CRYSTAL) phase III trial enrolled 599 patients to receive FOLFIRI plus cetuximab and 599 patients in the arm with FOLFIRI alone [210].”
MethodDuda, D. G., Willett, C. G., Ancukiewicz, M., Tomaso, E., Shah, M., Czito, B. G., Bentley, R., Poleski, M., Lauwers, G. Y., Carroll, M., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0029 · Cited by 94
Beppu, T., Miyamoto, Y., Sakamoto, Y., Imai, K., Nitta, H., Hayashi, H., Chikamoto, A., Watanabe, M., Ishiko, T., & Baba, H. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3577-x · Cited by 95
Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer
Goldstein, D. A., Ahmad, S. B., Chen, Q., Ayer, T., Howard, D. H., Lipscomb, J., El‐Rayes, B. F., & Flowers, C. R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.9569 · Cited by 100
Silberhumer, G. R., Paty, P. B., Denton, B. T., Guillem, J. G., Gönen, M., Araújo, R. L. C., Nash, G. M., Temple, L. K. F., Allen, P. J., DeMatteo, R. P., et al. (2016) · Surgery · doi:10.1016/j.surg.2016.02.029 · Cited by 94
“Furthermore, the use of chemotherapy prior to a staged liver operation is still an issue of debate, because it only showed a benefit for progression-free survival but not for OS.32,33 Nevertheless, earlier initiation of adjuvant chemotherapy will be enabled after complete tumor clearance by means of a combined operati…”
Cho, Y., Yoon, T., Jang, E., Hong, K. S., Lee, S. Y., Kim, O. R., Park, C.-S., Kim, Y.-J., Yi, G., & Chang, K. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.08.004 · Cited by 105
Therapeutic strategy in unresectable metastatic colorectal cancer
Chibaudel, B., Tournigand, C., André, T., & de Gramont, A. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011431592 · Cited by 103
“In patients with KRAS wild-type tumors, the addition of cetuximab to either FOLFIRI (CRYSTAL) or FOLFOX (OPUS) produced an improvement in median PFS (HR = 0.68 and 0.54) [Van Cutsem et al. 2009; Bokemeyer et al. 2009].”
BackgroundInfluentialAndré, T., Blons, H., Mabro, M., Chibaudel, B., Bachet, J., Tournigand, C., Bennamoun, M., Artru, P., Nguyen, S., Ebenezer, C., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds465 · Cited by 98
Long-term outcomes of patients with 10 or more colorectal liver metastases
Allard, M., Adam, R. A., Giuliante, F., Lapointe, R. W., Hubert, C., IJzermans, J. N. M., Mirza, D. F., Elias, D. M., Laurent, C., Gruenberger, T., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.218 · Cited by 99
“…techniques have pushed the boundaries of resectability while the introduction of efficient cytotoxic agents in association with targeted therapies (Cutsem et al, 2009; Kabbinavar et al, 2009) have markedly increased tumour response rate and chance for surgery in patients with unresectable disease…”
BackgroundQiu, L., Mao, C., Zhang, J., Zhu, X.-D., Liao, R.-Y., Xue, K., Li, J., & Chen, Q. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.05.022 · Cited by 105
Cohn, A. L., Tabernero, J. M., Maurel, J., Nowara, E., Sastre, J., Chuah, B., Валериевич, К. М., Sakaeva, D., Mitchell, E. P., Dubey, S., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt057 · Cited by 97
Luo, H., Li, Y., Wang, W., Wang, Z. Q., Yuan, X., Ma, D., Wang, F., Zhang, D. S., Lin, D., Lin, Y., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw101 · Cited by 99
“Recently, new biological agents, including cetuximab, panitumumab, bevacizumab, aflibercept and regorafenib, have expanded the treatment options for mCRC [6-9].”
BackgroundMuckenhuber, A., Berger, A. K., Schlitter, A. M., Steiger, K., Konukiewitz, B., Trumpp, A., Eils, R., Werner, J., Friess, H., Esposito, I., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2180 · Cited by 93
Lacouture, M. E., Anadkat, M. J., Jatoi, A., Garawin, T., Bohac, C., & Mitchell, E. P. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.12.004 · Cited by 110
“Incidence of Dermatologic Toxicities 10 Dermatologic toxicity of any grade occurs in most patients who receive anti-EGFR 11 therapy, and approximately 10% to 20% of patients experienced grade 3 or 4 12 toxicity.(4,15,35,36) The overall incidence of grade 3 or 4 skin toxicity is greater in phase 3 13 studies of anti-EG…”
BackgroundMethodInfluentialNew Trends in the Therapeutic Approach to Metastatic Colorectal Cancer
Sánchez-Gundín, J., Fernández-Carballido, A. M., Valdivieso, L. M., Barreda-Hernández, D., & Torres‐Suárez, A. I. (2018) · International Journal of Medical Sciences · doi:10.7150/ijms.24453 · Cited by 100
“study) [29] comparing FOLFIRI/cetuximab with FOLFIRI alone group provided confirmation that FOLFIRI/ cetuximab increased RR (46.”
ResultEl-Deiry, W. S., Vijayvergia, N., Xiu, J., Scicchitano, A., Lim, B., Yee, N. S., Harvey, H. A., Gatalica, Z., & Reddy, S. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1113356 · Cited by 91
Collazo-Lorduy, A., Castillo-Martín, M., Wang, L., Patel, V. G., Iyer, G., Jordan, E., Al‐Ahmadie, H. A., Leonard, I., Oh, W. K., Zhu, J., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.04.037 · Cited by 92
“However, in 2009, on the basis of emerging evidence demonstrating that activating KRAS mutations (resulting in constitutively activated MAPK signaling downstream of EGFR) conferred resistance to treatment, the US Food and Drug Administration restricted use of anti-EGFR antibodies to patients with wild-type KRAS tumors…”
U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer
Koganemaru, S., Kuboki, Y., Koga, Y., Kojima, T., Yamauchi, M., Maeda, N., Kagari, T., Hirotani, K., Yasunaga, M., Matsumura, Y., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0452 · Cited by 90
“therapy with anti-HER2 antibody (trastuzumab) and lapatinib have shown activity in patients with KRAS codon 12/13 wild-type/HER2 positive mCRC in clinical trials (12-14).”
BackgroundSchoffelen, R., Boerman, O. C., Goldenberg, D. M., Sharkey, R. M., van Herpen, C. M. L., Franssen, G. M., McBride, W. J., Chang, C.-H., Rossi, E. A., van der Graaf, W. T. A., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.376 · Cited by 98
“…and the anti-epidermal growth factor receptor antibodies, cetuximab or panitumumab, can improve patient outcome when combined with chemotherapy (Hurwitz et al, 2004; Giantonio et al, 2007; Amado et al, 2008; Saltz et al, 2008; Bokemeyer et al, 2009; Tol et al, 2009; Van Cutsem et al, 2009).”
BackgroundThe Emerging Potential for Network Analysis to Inform Precision Cancer Medicine
Öztürk, K., Dow, M. T., Carlin, D. E., Bejar, R. L., & Carter, H. K. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.06.016 · Cited by 98
Kinugasa, Y., Uehara, K., Yamaguchi, K., Saito, Y., Murofushi, K. N., Sugai, T., Ishiguro, M., Ishihara, S., Ueno, H., Oka, S., et al. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02899-8 · Cited by 112
Tabernero, J. M., Ciardiello, F., Rivera, F., Rodríguez-Braun, E., Ramos, F. J., Martinelli, E., Vega-Villegas, M. E., Roselló, S., Liebscher, S., Kisker, O., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp549 · Cited by 99
Baas, J. M., Krens, L. L., Guchelaar, H.-J., Morreau, H., & Gelderblom, H. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0024 · Cited by 89
Randomized Phase II Trial Designs With Biomarkers
Freidlin, B., McShane, L. M., Polley, M. C., & Korn, E. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3946 · Cited by 93
Tabernero, J. M., García‐Carbonero, R., Cassidy, J., Sobrero, A. F., Cutsem, E. V., Köhne, C.-H., Tejpar, S., Gladkov, O. A., Давиденко, І., Salazar, R., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0107 · Cited by 95
Self-citationvan de Haar, J., Ma, X., Ooft, S. N., van der Helm, P. W., Hoes, L. R., Mainardi, S., Pinato, D. J., Sun, K., Salvatore, L., Tortora, G., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02240-8 · Cited by 83
Early-Onset Colorectal Cancer: Current Insights
Ullah, F., Pillai, A. B., Omar, N., Dima, D., & Harichand, S. (2023) · Cancers · doi:10.3390/cancers15123202 · Cited by 101
Lin, H., Landersdorfer, C. B., London, D., Meng, R., Lim, C., Lin, C., Lin, S., Tang, H., Brown, D. L., Scoy, B. V., et al. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1001073 · Cited by 95
Al‐Ahmadie, H. A., Iyer, G., Janakiraman, M., Lin, O., Heguy, A., Tickoo, S. K., Fine, S. W., Gopalan, A., Chen, Y., Balar, A., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2892 · Cited by 88
Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy
Tan, L., Zhang, J., Wang, Y., Wang, X., Wang, Y., Zhang, Z., Shuai, W., Wang, G., Chen, J., Wang, C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01714 · Cited by 88
Hofheinz, R.-D., Deplanque, G., Komatsu, Y., Kobayashi, Y., Ocvirk, J., Racca, P., Guenther, S., Zhang, J., Lacouture, M. E., & Jatoi, A. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0051 · Cited by 88
Liu, X., Mody, K., Abreu, F. B. D., Pipas, J. M., Peterson, J. D., Gallagher, T. L., Suriawinata, A. A., Ripple, G. H., Hourdequin, K. C., Smith, K. D., et al. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2014.225565 · Cited by 89
Steele, N., Anthony, A., Saunders, M., Esmarck, B., Ehrnrooth, E., Kristjansen, P. E. G., Nihlén, A., Hansen, L. T., & Cassidy, J. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.599 · Cited by 87
“Cetuximab, administered intravenously (i.v.) on a weekly basis, improves tumour response rate and progression-free survival when combined with standard chemotherapy for metastatic CRC (Bokemeyer et al, 2009; Van Cutsem et al, 2009).”
BackgroundGeneral Aspects of Colorectal Cancer
Centelles, J. J. (2012) · ISRN Oncology · doi:10.5402/2012/139268 · Cited by 120
KRAS Mutation Testing in Human Cancers: The Pathologist's Role in the Era of Personalized Medicine
Wang, H. L., Lopategui, J. R., Amin, M. B., & Patterson, S. D. (2010) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181c6962f · Cited by 99
Tumour molecular profiling for deciding therapy—the French initiative
Nowak, F., Soria, J., & Calvo, F. M. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.42 · Cited by 91
Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline
Goffin, J. R., & Zbuk, K. M. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.08.007 · Cited by 104
“The addition of cetuximab to FOLFIRI in the 1st-line treatment of mCRC was explored in the CRYSTAL (Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer) trial.(103) Nearly 1200 patients were randomized to receive FOLFIR with or without cetuximab.”
BackgroundMethodTao, Z., Blanc, J. M. L., Wang, C., Zhan, T., Zhuang, H., Wang, P., Yuan, Z., & Lü, B. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0589 · Cited by 100
“Recent findings highlight that KRAS mutations act as a negative predictive marker for tumor response in patients with NSCLCs treated with adjuvant chemotherapy or anti-EGFR therapies (7, 27, 34, 35).”
BackgroundPrognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer
Sawada, K., Nakamura, Y., Yamanaka, T., Kuboki, Y., Yamaguchi, D., Yuki, S., Yoshino, T., Komatsu, Y., Sakamoto, N., Okamoto, W., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.05.006 · Cited by 85
Modest, D. P., Karthaus, M., Fruehauf, S., Graeven, U., Müller, L., König, A. O., Fischer von Weikersthal, L., Caca, K., Kretzschmar, A., Goekkurt, E., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01332 · Cited by 86
“of neurotoxicity) are associated with toxicities that frequently impair the tolerability and the continuation of treatment.(17-21) Therefore, in the preantibody era, maintenance therapy with fluoropyrimidineswas established following induction therapy with fluoropyrimidines and oxaliplatin on the basis of the results…”
BackgroundYoshino, T., Cervantes, A. M. R., Bando, H., Martinelli, E., Oki, E., Xu, R., Mulansari, N. A., Babu, K. G., Lee, M. A., Tan, C., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101558 · Cited by 105
Mattia, E. D., Cecchin, E., & Toffoli, G. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.05.003 · Cited by 97
Puig, I., Chicote, I., Tenbaum, S. P., Arqués, O., Herance, J. R., Gispert, J. D., Jimenez, J., Landolfi, S., Caci, K., Allende, H., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1740 · Cited by 86
“It significantly improves the response of patients with advanced colon cancer to conventional chemotherapy increasing their overall survival (3, 4).”
BackgroundHazama, S., Nakamura, Y., Tanaka, H., Hirakawa, K., Tahara, K., Shimizu, R., Ozasa, H., Etoh, R., Sugiura, F., Okuno, K., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-108 · Cited by 86
Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks
Roukos, D. H. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.81 · Cited by 87
Wainberg, Z. A., Lin, L. S., DiCarlo, B. A., Dao, K. M., Patel, R., Park, D., Wang, H.-J., Elashoff, R. M., Ryba, N., & Hecht, J. R. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.280 · Cited by 89
“Mutations in KRAS have recently become established as a negative predictive marker for the benefit of EGFR monoclonal antibodies in advanced colorectal cancer (Amado et al, 2008; Van Cutsem et al, 2009).”
BackgroundPek, M., Yatim, S. M. J. M., Chen, Y., Li, J., Gong, M., Jiang, X., Zhang, F., Zheng, J., Wu, X., & Yu, Q. (2017) · Oncogene · doi:10.1038/onc.2017.120 · Cited by 86
Precision medicine in colorectal cancer: the molecular profile alters treatment strategies
Tran, N. H., Cavalcante, L. L., Lubner, S. J., Mulkerin, D. L., LoConte, N. K., Clipson, L., Matkowskyj, K. A., & Deming, D. A. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015591952 · Cited by 84
Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer
Boisen, M. K., Johansen, J. S., Dehlendorff, C., Larsen, J. S., Østerlind, K., Hansen, J., Nielsen, S. E., Pfeiffer, P., Tarpgaard, L. S., Holländer, N. H., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt253 · Cited by 92
Zhang, B., Brahma, R. K., Zhu, L., Feng, J., Hu, S., Qian, L., Du, S., Yao, S. Q., & Ge, J. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c08886 · Cited by 90
Treatment of Metastatic Colorectal Cancer
Davies, J. M., & Goldberg, R. M. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.05.009 · Cited by 93
Chang, S., Zhang, L., Xu, S., Luo, J., Lu, X., Zhang, Z., Xu, T., Liu, Y., Tu, Z., Xu, Y., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201591k · Cited by 83
Bronte, G., Silvestris, N., Castiglia, M., Galvano, A., Passiglia, F., Sortino, G., Cicero, G., Rolfo, C., Peeters, M., Bazan, V., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4959 · Cited by 84
Cushman, S. M., Jiang, C., Hatch, A. J., Shterev, I. D., Sibley, A. B., Niedzwiecki, D., Venook, A. P., Owzar, K., Hurwitz, H. I., & Nixon, A. B. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2313 · Cited by 90
Yabar, C. S., & Winter, J. M. (2016) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2016.04.003 · Cited by 94
Guo, L., Wang, Y., Yang, W., Wang, C., Guo, T., Yang, J., Shao, Z., Cai, G., Cai, S., Zhang, L., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.04.029 · Cited by 92
Digestive cancers: mechanisms, therapeutics and management
Zhan, T., Betge, J., Schulte, N., Dreikhausen, L., Hirth, M., Li, M., Weidner, P., Leipertz, A., Teufel, A., & Ebert, M. P. A. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02097-4 · Cited by 100
Are RAS mutations predictive markers of resistance to standard chemotherapy?
Loriot, Y., Mordant, P., Deutsch, É., Olaussen, K. A., & Soria, J. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.106 · Cited by 92
“The CRYSTAL study evaluated the effect of KRAS mutations on the outcome of patients treated with irinotecan-based chemotherapy (FOLFIRI) with or without cetuximab”
Inno, A., Di Salvatore, M., Cenci, T., Martini, M., Orlandi, A., Strippoli, A., Ferrara, A. M., Bagalà, C., Cassano, A., Larocca, L. M., et al. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.03.028 · Cited by 83
Karoui, M., Viganò, L., Goyer, P., Ferrero, A., Luciani, A., Aglietta, M., Delbaldo, C., Cirillo, S., Capussotti, L., & Cherqui, D. (2010) · British journal of surgery · doi:10.1002/bjs.7128 · Cited by 92
Colorectal Cancer Biomarkers and the Potential Role of Cancer Stem Cells
Langan, R. C., Mullinax, J. E., Raiji, M. T., Upham, T. C., Summers, T. A., Stojadinovic, A., & Avital, I. (2013) · Journal of Cancer · doi:10.7150/jca.5832 · Cited by 88
Kuboki, Y., Yamashita, S., Niwa, T., Ushijima, T., Nagatsuma, A. K., Kuwata, T., Yoshino, T., Doi, T., Ochiai, A., & Ohtsu, A. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv508 · Cited by 88
Westwood, M. E., van Asselt, A. D. I., Ramaekers, B. L. T., Whiting, P. F., Joore, M. A., Armstrong, N., Noake, C., Ross, J., Severens, J. L., & Kleijnen, J. (2014) · Health Technology Assessment · doi:10.3310/hta18620 · Cited by 88
“Subgroup analyses of patients tested for KRAS mutation status from randomised controlled trials (RCTs) have shown that treatment with the EGFR-inhibiting monoclonal antibody cetuximab in combination with standard chemotherapy can increase progression-free survival (PFS) and tumour response in patients with KRAS wild-t…”
BackgroundResultInfluentialNovel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin
Suzuki, K., Kokuryo, T., Senga, T., Yokoyama, Y., Nagino, M., & Hamaguchi, M. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01504.x · Cited by 85
Gastric cancer and the epoch of immunotherapy approaches
Niccolai, E., Taddei, A., Prisco, D., & Amedei, A. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i19.5778 · Cited by 88
Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer
Dienstmann, R., Salazar, R., & Tabernero, J. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e149 · Cited by 82
Role of Adjuvant Therapy After Resection of Colorectal Cancer Liver Metastases
Power, D. G., & Kemeny, N. E. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9340 · Cited by 82
Lam, V. W. T., Laurence, J. M., Pang, T., Johnston, E. S., Hollands, M. J., Pleass, H. C. C., & Richardson, A. J. (2013) · HPB · doi:10.1111/hpb.12083 · Cited by 89
BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy
Teng, H., Huang, Y.-C., Lin, J., Chen, W., Lin, T., Jiang, J., Yen, C., Li, A. F., Wang, H., Chang, S., et al. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23063 · Cited by 91
“Thus, these patients have fewer opportunities to receive hepatic resection due to advanced disease, a poor response to induction chemotherapy, and multiple metastasis [6,7,13,14,22,23,25].”
BackgroundMultiplex Mutation Screening by Mass Spectrometry
Beadling, C., Heinrich, M. C., Warrick, A., Forbes, E. M., Nelson, D., Justusson, E., Levine, J., Neff, T. L., Patterson, J., Presnell, A., et al. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2011.04.003 · Cited by 85
Panitumumab in Patients with KRAS Wild-Type Colorectal Cancer after Progression on Cetuximab
Wadlow, R. C., Hezel, A. F., Abrams, T. A., Blaszkowsky, L. S., Fuchs, C. S., Kulke, M. H., Kwak, E. L., Meyerhardt, J. A., Ryan, D. P., Szymonifka, J., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0452 · Cited by 80
Bray, S. M., Lee, J., Kim, S. T., Hur, J. Y., Ebert, P. J., Calley, J. N., Wulur, I. H., Gopalappa, T., Wong, S. S., Qian, H.-R., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51981-5 · Cited by 82
Naringin inhibits colorectal cancer cell growth by repressing the PI3K/AKT/mTOR signaling pathway
Cheng, H., Jiang, X., Zhang, Q., Ma, J., Cheng, R., Yong, H., Shi, H., Zhou, X., Ge, L., & Gao, G. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8649 · Cited by 79
Metadata
- Authors
- Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., Roh, J. K., Folprecht, G., Ruff, P., Stroh, C., Tejpar, S., Schlichting, M., Nippgen, J., & Rougier, P.
- Affiliations
- Klinikum Oldenburg (DE)
- Moscow City Oncology Hospital №62 (RU)
- Petz Aladár Megyei Oktató Kórház (HU)
- National University Hospital (SG)
- Yonsei University (KR)
- University Hospital Carl Gustav Carus (DE)
- University of the Witwatersrand (ZA)
- Merck KGaA, Darmstadt (Germany) (DE)
- Universitair Ziekenhuis Leuven (BE)
- Hôpital Ambroise-Paré (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-04-02
- Volume
- 360
- Issue
- 14
- Pages
- 1408-1417
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2095201384
- Cited by
- 3,877
- References
- 34
- Citations by year
- 2026: 83 · 2025: 87 · 2024: 105 · 2023: 136 · 2022: 169 · 2021: 173 · 2020: 194 · 2019: 199 · 2018: 172 · 2017: 221 · 2016: 275 · 2015: 307 · 2014: 337 · 2013: 328 · 2012: 331
- FWCI
- 179.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- cetuximab, FOLFIRI, metastatic colorectal cancer, first-line therapy, KRAS mutation status, epidermal growth factor receptor, progression-free survival, overall survival, treatment response, adverse events, irinotecan, 5-fluorouracil, leucovorin, skin reactions, diarrhea, infusion reactions, anti-EGFR therapy
- MeSH terms
- Cetuximab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Genes, ras, Colorectal Neoplasms, Disease Progression, Kaplan-Meier Estimate, Young Adult, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.